The buy-side view

Since December, at least 21 biotech companies have filed for public offerings, and everyone knows there are more coming. Just how fund managers wade through those competing demands for money will play an important role in determining over the next few years which biotech companies will have adequate capital to develop their products and which will not.

BioCentury talked to fund managers and analysts, ranging from healthcare and smallcap funds to private money managers. We asked them how they cope with the onslaught of offerings and what kinds of screens they use to narrow their choices and make investment picks...